VivoSeq
Other

High Blood Pressure

0

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

High Blood Pressure is an early-stage landscape with 0 programs across 9 companies. The most active players are Novartis, Bayer, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Completed31 · 91%
Withdrawn1 · 3%
Terminated1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

34 trials

Innovative Tools to Expand Music-Inspired Strategies for Blood Pressure and Stroke Prevention
Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT07386535·1,412 enrolled
Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure
Completed·SSeoul National University Bundang Hospital·N/A·NCT03255551·50 enrolled
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT01961323·70 enrolled
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Completed·Eli Lilly logoEli Lilly·Phase 3·NCT00549302·357 enrolled
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Completed·Novartis logoNovartis·Phase 3·NCT00386607·601 enrolled
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00143234·1,825 enrolled
Dietary Counseling or Potassium Supplement to Increase Potassium Intake in Patients With High Blood Pressure
Completed·OOttawa Hospital Research Institute·Phase 3·NCT03809884·7 enrolled
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
Completed·Novartis logoNovartis·Phase 3·NCT00219128·671 enrolled
A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure
Completed·Takeda logoTakeda·Phase 3·NCT04668157·10 enrolled
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
Completed·Novartis logoNovartis·Phase 3·NCT00260923·641 enrolled
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Completed·GSK logoGSK·Phase 1·NCT00537043·24 enrolled
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
Completed·Bayer logoBayer·Phase 2·NCT04507061·243 enrolled
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
Completed·Novartis logoNovartis·Phase 4·NCT00171353·109 enrolled
A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
Completed·Takeda logoTakeda·N/A·NCT05107960·5 enrolled
A Study of LY2623091 in Participants With High Blood Pressure
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT02194465·304 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)